

Bastian Keck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6839239/publications.pdf>

Version: 2024-02-01

37
papers

1,546
citations

430843

18
h-index

395678

33
g-index

37
all docs

37
docs citations

37
times ranked

2724
citing authors

#	ARTICLE	IF	CITATIONS
1	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e9-63.e18.	1.6	5
2	Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions. <i>Cells</i> , 2021, 10, 1315.	4.1	4
3	High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. <i>Life</i> , 2021, 11, 642.	2.4	3
4	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. <i>Cancers</i> , 2020, 12, 2794.	3.7	17
5	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
6	Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). <i>Oncologist</i> , 2019, 24, e1341-e1350.	3.7	28
7	Rare Subentities of Urothelial Bladder Carcinoma. , 2019, , 413-421.		0
8	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. <i>Histopathology</i> , 2019, 75, 865-875.	2.9	35
9	Rare Subentities of Urothelial Bladder Carcinoma. , 2019, , 1-8.		0
10	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	3.4	148
11	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , 2019, 12, 661-668.	3.7	16
12	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019, 106, 234-243.	2.8	75
13	Molecular Markers Increase Precision of the European Association of Urology Nonâ€“Muscle-Invasive Bladder Cancer Progression Risk Groups. <i>Clinical Cancer Research</i> , 2018, 24, 1586-1593.	7.0	79
14	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. <i>Oncotarget</i> , 2018, 9, 15001-15014.	1.8	33
15	Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. <i>Tumor Biology</i> , 2016, 37, 10177-10185.	1.8	41
16	Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. <i>PLoS ONE</i> , 2015, 10, e0128235.	2.5	13
17	Piwi1 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients. <i>Molecular Medicine</i> , 2015, 21, 371-380.	4.4	21
18	Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1234-1239.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Identification of ZNF217, hnRNP κ , VEGF β and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 775-784.	5.1	70
20	Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review. <i>BMC Cancer</i> , 2013, 13, 131.	2.6	13
21	Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. <i>BMC Cancer</i> , 2013, 13, 71.	2.6	74
22	SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 3669-3674.	1.5	11
23	MRI-guided core biopsy of the prostate in the supine position—introduction of a simplified technique using large-bore magnet systems. <i>European Radiology</i> , 2013, 23, 1415-1419.	4.5	9
24	Is gender becoming relevant in uro-oncological research? A bibliographical analysis. <i>World Journal of Urology</i> , 2013, 31, 1065-1072.	2.2	9
25	Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. <i>World Journal of Urology</i> , 2013, 31, 1023-1028.	2.2	26
26	Bladder cancer – the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov. <i>BMC Urology</i> , 2013, 13, 56.	1.4	11
27	Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme. <i>European Urology</i> , 2013, 63, 977-982.	1.9	70
28	Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder. <i>Annals of Surgical Oncology</i> , 2013, 20, 2440-2445.	1.5	32
29	Clinical Course of Plasmacytoid Urothelial Carcinoma of the Upper Urinary Tract: A Case Report. <i>Urologia Internationalis</i> , 2012, 89, 120-122.	1.3	9
30	Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. <i>BMC Medicine</i> , 2012, 10, 96.	5.5	30
31	MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. <i>International Journal of Cancer</i> , 2012, 130, 611-621.	5.1	141
32	Sonographic diagnosis of a posttraumatic arteriocavernosal fistula resulting in high-flow priapism. <i>Journal of Clinical Ultrasound</i> , 2012, 40, 60-62.	0.8	8
33	Do urology journals enforce trial registration? A cross-sectional study of published trials. <i>BMJ Open</i> , 2011, 1, e000430-e000430.	1.9	27
34	Toward the blood-borne miRNome of human diseases. <i>Nature Methods</i> , 2011, 8, 841-843.	19.0	339
35	Diagnostic challenge of atypical colorectal metastasis to the renal pelvis. <i>International Journal of Colorectal Disease</i> , 2011, 26, 523-524.	2.2	0
36	The plasmacytoid carcinoma of the bladder—rare variant of aggressive urothelial carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 346-354.	5.1	94

#	ARTICLE	IF	CITATIONS
37	Mutational Activation of <i>FGFR3</i> is Not Involved in the Development of Prostate Cancer. <i>Pathobiology</i> , 2010, 77, 249-252.	3.8	4